STT FA Bio 'GID' GI DYNAMICS
Developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S.
Revenue increased to approximately US$0.5 million for the 3rd Quarter compared to approximately US$0.1 million for the same period last year. The increase in the Company’s revenue in the Quarter was primarily a result of a 163% increase in revenue from sales in Europe and revenue from sales in the Middle East with no corresponding sales in the same period last year.
GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial) in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference December 3, 2013.
Has cash of $44m in the bank
I'm expecting a turn around in the SP as this company move forward.
- Forums
- ASX - Short Term Trading
- short term trading week stating 25th nov
short term trading week stating 25th nov, page-40
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)